Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 44Myeloid 14Lymphoid 5Classical hematology 2Sarcoma 1

Conditions

Sarcoma 1Osteosarcoma 1

Interventions

Cyclophosphamide 22Specimen Handling 20Magnetic Resonance Spectroscopy 20pembrolizumab 18Nivolumab 18Radiotherapy 17Biopsy 16Doxorubicin 15Temozolomide 14Radiation 14X-Rays 9Irinotecan 9Ipilimumab 9Ifosfamide 9fludarabine 8Phantoms, Imaging 8Etoposide 8cabozantinib 7Vincristine 7Carboplatin 7Bevacizumab 7regorafenib 6Sirolimus 6palbociclib 5olaparib 5fludarabine phosphate 5durvalumab 5Vinorelbine 5Sunitinib 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Azacitidine × Sarcoma × Clear all
NCT03628209 2026-02-05

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
21 enrolled
Sarcoma

Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡